Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EZH2 loss promotes gastric squamous cell carcinoma [RNA-seq]

ABSTRACT: Gastric Squamous Cell Carcinoma (GSCC) is a rare subtype of gastric cancer with unique histopathology while gastric adenosquamous carcinoma (GASC), which partially shares features of GSCC, is more frequent. Both GSCC and GASC have poor prognosis but the molecular mechanisms underlying these malignancies are unknown. Here, we performed genomics analyses of eleven GSCC samples and found that epigenetic regulation genes were among the most frequently mutated genes. Among them was Enhancer of zeste homolog 2 (EZH2), which was also significantly downregulated in GASC, compared to gastric adenocarcinoma (GAC). Ezh2 loss led to squamous feature both in gastric organoids in vitro and in vivo. Importantly, Ezh2 deficiency, together with Trp53 and Pten loss, both of which were also frequently mutated in GSCC, gave rise to full-blown GSCC in mice. Mechanistically, we found that Ezh2 could repress the expression of Transcription factor AP-2 gamma (Tfap2c), a transcription factor with the ability to initiate epidermal squamous differentiation, through H3K27 methylation. Disruption of Tfap2c reversed Ezh2 loss-driven GSCC into GAC and reduced its resistance to chemo treatment. Our study revealed the mechanisms of GSCC/GASC tumorigenesis and shed light on future treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE254316 | GEO | 2025/05/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

EZH2 loss promotes gastric squamous cell carcinoma [CUT&Tag]

Project description:Gastric Squamous Cell Carcinoma (GSCC) is a rare subtype of gastric cancer with unique histopathology while gastric adenosquamous carcinoma (GASC), which partially shares features of GSCC, is more frequent. Both GSCC and GASC have poor prognosis but the molecular mechanisms underlying these malignancies are unknown. Here, we performed genomics analyses of eleven GSCC samples and found that epigenetic regulation genes were among the most frequently mutated genes. Among them was Enhancer of zeste homolog 2 (EZH2), which was also significantly downregulated in GASC, compared to gastric adenocarcinoma (GAC). Ezh2 loss led to squamous feature both in gastric organoids in vitro and in vivo. Importantly, Ezh2 deficiency, together with Trp53 and Pten loss, both of which were also frequently mutated in GSCC, gave rise to full-blown GSCC in mice. Mechanistically, we found that Ezh2 could repress the expression of Transcription factor AP-2 gamma (Tfap2c), a transcription factor with the ability to initiate epidermal squamous differentiation, through H3K27 methylation. Disruption of Tfap2c reversed Ezh2 loss-driven GSCC into GAC and reduced its resistance to chemo treatment. Our study revealed the mechanisms of GSCC/GASC tumorigenesis and shed light on future treatment.

2025-05-18 | GSE254317 | GEO

EZH2 loss promotes gastric squamous cell carcinoma

Project description:EZH2 loss promotes gastric squamous cell carcinoma

| PRJNA1069729 | ENA

EZH2 loss promotes gastric squamous cell carcinoma [RNA-seq]

Project description:EZH2 loss promotes gastric squamous cell carcinoma [RNA-seq]

| PRJNA1069735 | ENA

EZH2 loss promotes gastric squamous cell carcinoma [CUT&Tag]

Project description:EZH2 loss promotes gastric squamous cell carcinoma [CUT&Tag]

| PRJNA1069734 | ENA

Comprehensive profile and contrastive analysis of circular RNA in cervical squamous carcinoma and adenocarcinoma

Project description:To contrastively analyze the expression pattern of circRNAs in cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma variants. CircRNAs expression in cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma tissues together with the adjacent normal tissues were profiled by high-throughput RNA sequencing.

2022-12-31 | GSE208089 | GEO

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Project description:Adenosquamous lung tumors may result from cellular plasticity. We demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant models. Chromatin analysis reveals loss of H3K27me3 and gain of H3K27ac and H3K4me3 at squamous lineage genes, included Sox2, ΔNp63 and Ngfr. SCC lesions have higher levels of the H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential Polycomb Repressive Complex 2 (PRC2) subunit EED in the SCC lesions.

2017-02-02 | GSE94365 | GEO

ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis [ChIP-seq]

Project description:Lung cancer remains the leading cause of cancer death. Genome sequencing of lung tumors from patients with Squamous Cell Carcinoma has identified SMAD4 to be frequently mutated. Here we used a novel mouse model to determine the molecular mechanisms regulated by loss of Smad4 which lead to lung cancer progression. Mice with ablation of Pten and Smad4 in airway epithelium developed metastatic adenosquamous tumors. Comparative transcriptomic and in vivo cistromic analyses determined that loss of PTEN and SMAD4 resulted in activation of the ELF3 and the ErbB2 pathway due to decreased ERRFI1M-bM-^@M-^Ys expression, a negative regulator of ERBB2 in mice and human cells. The combinatorial inhibition of ErbB2 and Akt signaling attenuated tumor progression and cell invasion, respectively. Expression profiles analysis of human lung tumors substantiated the importance of the ErbB2/Akt/ELF3 signaling pathway as both prognostic biomarkers and therapeutic drug targets for treating lung cancer. Examination of genome-wide SMAD4 binding in 7-month-old Ptend/d mouse lung.

2015-03-05 | E-GEOD-57177 | biostudies-arrayexpress

Targeting EZH2 methyltransferase activity in ARID1A mutated cells as a synthetic lethal therapeutic strategy

Project description:ARID1A, an epigentic modifier, is often mutated in ovarian clear cell carcinoma (OCCC). In addition, EZH2 is frequently upregulated in OCCC. Inhibtion of EZH2 with an inhibitor (GSK126) selectively inhibits ARID1A-mutated cells. This study was designed to understand changes in gene expression profiles following EZH2 inhibition or ARID1A restoration. Chromatin remodelers such as ARID1A are frequently mutated in a broad array of cancers. However, targeted cancer therapy based on ARID1A mutation status has not been described. Intriguingly, ARID1A mutated cancers typically lack genomic instability, suggesting significant involvement of epigenetic mechanisms. Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated cells. Remarkably, ARID1A mutation status correlated with response to EZH2 inhibitor. Genome-wide profiling revealed antagonistic roles of ARID1A and EZH2 in gene regulation. Further, we identified PIK3IP1 as a direct ARID1A/EZH2 target gene whose upregulation contributes to the observed synthetic lethality in the EZH2 inhibitor treated ARID1A mutated cells. Significantly, EZH2 inhibitor caused the regression of established ARID1A mutated tumors in vivo. Together, this data demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition. They indicate that pharmacological inhibition of EZH2 represents a novel treatment strategy for ARID1A mutated cancers.

2015-01-20 | E-GEOD-54979 | biostudies-arrayexpress

Targeting EZH2 methyltransferase activity in ARID1A mutated cells as a synthetic lethal therapeutic strategy

2015-01-20 | GSE54979 | GEO

ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis [ChIP-seq]

Project description:Lung cancer remains the leading cause of cancer death. Genome sequencing of lung tumors from patients with Squamous Cell Carcinoma has identified SMAD4 to be frequently mutated. Here we used a novel mouse model to determine the molecular mechanisms regulated by loss of Smad4 which lead to lung cancer progression. Mice with ablation of Pten and Smad4 in airway epithelium developed metastatic adenosquamous tumors. Comparative transcriptomic and in vivo cistromic analyses determined that loss of PTEN and SMAD4 resulted in activation of the ELF3 and the ErbB2 pathway due to decreased ERRFI1’s expression, a negative regulator of ERBB2 in mice and human cells. The combinatorial inhibition of ErbB2 and Akt signaling attenuated tumor progression and cell invasion, respectively. Expression profiles analysis of human lung tumors substantiated the importance of the ErbB2/Akt/ELF3 signaling pathway as both prognostic biomarkers and therapeutic drug targets for treating lung cancer.

2015-03-05 | GSE57177 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data